Safety analysis of Yttrium-90 resin microsphere selective internal radiation therapy on malignant liver tumors
10.12025/j.issn.1008-6358.2025.20250019
- VernacularTitle:钇-90树脂微球选择性内放射治疗肝脏恶性肿瘤的安全性分析
- Author:
Jia CAI
1
;
Shiwei TANG
1
;
Rongli LI
1
;
Mingxin KONG
1
;
Hongyan DING
1
;
Xiaofeng YUAN
1
;
Yuying HU
1
;
Ruimei LIU
1
;
Xiaoyan ZHU
1
;
Wenjun LI
1
;
Haibin ZHANG
1
;
Guanwu WANG
1
Author Information
1. Department of Interventional Radiology, Weifang People’s Hospital, Weifang 261000, Shangdong, China.
- Publication Type:Monographicreport:Yttrium-90microsphereinternalradiationtherapyonlivercancer
- Keywords:
Yttrium-90;
selective internal radiation therapy;
malignant liver tumor;
safety
- From:
Chinese Journal of Clinical Medicine
2025;32(1):24-29
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the safety of Yttrium-90 resin microsphere selective internal radiation therapy (90Y-SIRT) on malignant liver tumors. Methods A retrospective analysis was conducted on 64 patients with malignant liver tumors who underwent 90Y-SIRT from February 2023 to November 2024 at Weifang People’s Hospital. The clinical characteristics of the patients and the occurrence of adverse reactions after treatment were analyzed to assess the safety of 90Y-SIRT. Results Among the 64 patients, there were 52 males (81.25%) and 12 females (18.75%); the average age was (56.29±11.08) years. Seven patients (10.94%) had tumors with maximum diameter of less than 5 cm, 38 patients (59.38%) had tumors with maximum diameter of 5-10 cm, and 19 patients (29.68%) had tumors with maximum diameter of greater than 10 cm. There were 47 cases (73.44%) of solitary lesions and 17 cases (26.56%) of multiple lesions; 53 cases (82.81%) were primary liver cancers and 11 cases (17.19%) were metastatic liver cancers. Of the 64 patients, 63 successfully completed the Technetium-99m macroaggregated albumin (99mTc-MAA) perfusion test and received the 90Y-SIRT; one patient received 90Y-SIRT after the second 99mTc-MAA perfusion test due to a work error. The most common adverse reactions included grade 1 alanine aminotransferase (ALT) elevation in 26 cases (40.62%) and grade 2 in 2 cases (9.37%), grade 1 aspartate aminotransferase (AST) elevation in 27 cases (42.18%) and grade 2 in 7 cases (10.93%); grade 1 nausea in 17 cases (26.56%) and grade 2 in 6 cases (9.37%); grade 1 abdominal pain in 12 cases (18.75%), grade 2 in 5 cases (7.81%), and grade 3 in 1 case (1.56%); grade 1 vomiting in 11 cases (17.18%), grade 2 in 5 cases (7.81%), and grade 3 in 1 case (1.56%). Conclusion The adverse reactions of 90Y-SIRT for treating malignant liver tumors are mild, indicating good safety.
